GlassScriptPhysician profile
Kathryn L Elmore
NPI 1245325547
$12,117.41
in general payments reported to CMS, 2019-2025
27 companies · $529 in 2025
The $529 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $398 · 2021: $786 · 2022: $1,109 · 2023: $7,740 · 2024: $1,113 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $5,250 · Food and Beverage: $2,589 · Travel and Lodging: $1,429 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $5,250.00 |
| Food and Beverage | $2,588.85 |
| Travel and Lodging | $1,428.84 |
| Education | $113.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $8,072.74 | 2019-2023 | Krystexxa |
| Amgen INC. | $895.48 | 2019-2025 | Krystexxa, Tavneos, Aranesp |
| Astrazeneca Pharmaceuticals LP | $749.85 | 2019-2025 | Farxiga |
| Aurinia Pharma U.S., INC. | $477.50 | 2021-2025 | Lupkynis |
| Daiichi Sankyo INC. | $221.16 | 2021-2023 | Injectafer |
| Fresenius USA Marketing, INC. | $217.35 | 2019-2024 | Korsuva, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $205.92 | 2021-2025 | |
| Travere Therapeutics, INC. | $195.47 | 2022-2025 | Filspari |
| Opko Pharmaceuticals, LLC | $184.00 | 2019-2024 | Rayaldee |
| Vifor Pharma, INC. | $150.91 | 2019-2023 | Korsuva, Veltassa |
| Otsuka America Pharmaceutical, INC. | $114.06 | 2019-2024 | Jynarque |
| Akebia Therapeutics INC | $94.48 | 2019-2020 | |
| Calliditas Therapeutics US INC. | $87.96 | 2023 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.45 | 2023-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $52.26 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $45.04 | 2023-2024 | Jardiance |
| Genzyme Corporation | $41.35 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.53 | 2019 | |
| Ani Pharmaceuticals, INC. | $29.24 | 2024 | Purified Cortrophin Gel |
| Alnylam Pharmaceuticals INC. | $29.17 | 2025 | Givlaari |
| Baxter Healthcare | $25.00 | 2022 | |
| Boston Scientific Corporation | $22.63 | 2025 | General - Pain Management |
| Novo Nordisk INC | $21.55 | 2025 | Ozempic |
| Apellis Pharmaceuticals, INC. | $19.94 | 2025 | Empaveli |
| Abbott Laboratories | $17.26 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Glaxosmithkline, LLC. | $14.81 | 2023 | Benlysta |
| Mallinckrodt Hospital Products INC. | $12.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Elmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.